Los Angeles Capital Management LLC Raises Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Los Angeles Capital Management LLC increased its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTXGet Rating) by 1,135.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 126,706 shares of the biopharmaceutical company’s stock after purchasing an additional 116,446 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.09% of TG Therapeutics worth $539,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Valeo Financial Advisors LLC raised its stake in TG Therapeutics by 145.6% in the second quarter. Valeo Financial Advisors LLC now owns 42,000 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 24,900 shares during the last quarter. Liberty One Investment Management LLC raised its stake in TG Therapeutics by 3,697.6% in the second quarter. Liberty One Investment Management LLC now owns 4,709 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 4,585 shares during the last quarter. Arizona State Retirement System raised its stake in TG Therapeutics by 12.0% in the second quarter. Arizona State Retirement System now owns 36,801 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 3,957 shares during the last quarter. CWM LLC raised its stake in TG Therapeutics by 4,871.4% in the second quarter. CWM LLC now owns 12,180 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 11,935 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in TG Therapeutics by 722.3% in the second quarter. Assenagon Asset Management S.A. now owns 2,088,952 shares of the biopharmaceutical company’s stock valued at $8,878,000 after buying an additional 1,834,924 shares during the last quarter. 72.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on TG Therapeutics in a research note on Wednesday, October 12th. They issued a “sell” rating for the company. Three equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $21.25.

TG Therapeutics Trading Up 63.4 %

Shares of NASDAQ:TGTX opened at $8.43 on Friday. TG Therapeutics, Inc. has a 52-week low of $3.48 and a 52-week high of $33.87. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -3.90 and a beta of 2.12. The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 0.53. The business has a 50-day moving average price of $6.08 and a 200-day moving average price of $5.97.

TG Therapeutics (NASDAQ:TGTXGet Rating) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.19. TG Therapeutics had a negative return on equity of 136.07% and a negative net margin of 4,144.49%. The firm had revenue of $0.59 million during the quarter, compared to analysts’ expectations of $0.09 million. Equities analysts predict that TG Therapeutics, Inc. will post -1.44 EPS for the current year.

About TG Therapeutics

(Get Rating)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.

Further Reading

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.